Develop Business Strategies Of Painful Diabetic Neuropathy Market Analysis to 2026

"The Latest Research Report PharmaPoint: Painful Diabetic Neuropathy - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Painful diabetic neuropathy is a late-stage complication that occurs in patients suffering from diabetes mellitus and is thought to affect up to half of patients with the disease. PDN manifests itself as a variety of syndromes which differ in clinical course, distribution, fibre involvement and, pathophysiology. Symptoms will vary from patient to patient however; the most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull/ache-like, which are often localized to the extremities, affecting the feet and hands.

Currently, there are only three approved therapies for the treatment of PDN, Pfizers Lyrica, Eli Lillys Cymbalta, and Grnenthal's Nucynta ER. Acorda Therapeutics has marketed an 8% capsaicin patch (Qutenza) which is approved for peripheral neuropathic pain and may be used in certain PDN syndromes. Outside of these drugs the market consists of off label use and generics.

GlobalData estimates that drug sales for PDN in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $7.1B at a CAGR of 8.7%. This growth will be driven by the launch of four late-stage pipeline products. The two highest selling drugs are expected to be ViroMeds VM202 and Daiichi-Sankyos mirogabalin besylate, which both address some of the unmet needs in the market.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1743198

Scope

- Overview of PDN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized PDN therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (typical and atypical) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PDN therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PDN therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global PDN therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PDN therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PDN therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Browse Complete Report with TOC @ https://www.marketresearchreports.biz/reports/1743198/pharmapoint-painful-diabetic-neuropathy-market-research-reports/toc

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 9

2 Painful Diabetic Neuropathy: Executive Summary 11
2.1 PDN Market Is Expected to Reach $7B by 2026 12
2.2 Partnerships and Licensing Agreements Are the Most Commonly Used Strategy 13
2.3 Drugs with Improved Safety and Efficacy Profiles Top the Unmet Needs 16
2.4 Big Opportunities for Companies Willing to Invest In Pathophysiology Research 17
2.5 Gene Therapy Is a Key Driver of Growth in the Global PDN Market 17
2.6 What Do the Physicians Think? 19

3 Introduction 24
3.1 Catalyst 24
3.2 Related Reports 25

4 Disease Overview 26
4.1 Overview 26
4.2 Classification or Staging Systems 28
4.3 Etiology and Pathophysiology 30
4.3.1 Etiology 30
4.3.2 Pathophysiology 31
4.4 Symptoms 33
4.5 Prognosis 35
4.6 Quality of Life 35

5 Epidemiology 36
5.1 Disease Background 36
5.2 Risk Factors and Comorbidities 37
5.3 Global and Historical Trends 37
5.3.1 US 38
5.3.2 5EU 39
5.3.3 Japan 39
5.4 Forecast Methodology 40
5.4.1 Sources 41
5.4.2 Forecast Assumptions and Methods 44
5.5 Epidemiological Forecast for PDN (2016-2026) 53
5.5.1 Total Prevalent Cases of PDN 53
5.5.2 Age-Specific Total Prevalent Cases of PDN 54
5.5.3 Sex-Specific Total Prevalent Cases of PDN 56
5.5.4 Total Prevalent Cases of PDN by Severity of Neuropathy 56
5.5.5 Total Prevalent Cases of Typical and Atypical PDN 57
5.5.6 Diagnosed Prevalent Cases of PDN 58
5.6 Discussion 59
5.6.1 Epidemiological Forecast Insight 59
5.6.2 Limitations of the Analysis 60
5.6.3 Strengths of the Analysis 61

View Sample PDF @ https://www.marketresearchreports.biz/reports/1743198/pharmapoint-painful-diabetic-neuropathy-market-research-reports.pdf

6 Disease Management 62
6.1 Diagnosis Overview 62
6.2 Treatment Overview 66
6.2.1 Treatment Guidelines and Leading Prescribed Drugs 67
6.2.2 Clinical Practice 68
6.2.3 Non-pharmacological Treatments 74
6.3 US 75
6.4 5EU 78
6.5 Japan 83

7 Competitive Assessment 87
7.1 Overview 87
7.2 Nucynta ER/Palexia SR (tapentadol) 88
7.2.1 Overview 88
7.2.2 Efficacy 90
7.2.3 Safety 91
7.2.4 SWOT Analysis 92
7.2.5 Forecast 92
7.3 Lyrica (pregabalin) 93
7.3.1 Overview 93
7.3.2 Efficacy 95
7.3.3 Safety 95
7.3.4 SWOT Analysis 97
7.3.5 Forecast 97
7.4 Cymbalta (duloxetine) 97
7.4.1 Overview 97
7.4.2 Efficacy 100
7.4.3 Safety 100
7.4.4 SWOT Analysis 101
7.4.5 Forecast 101

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.